drugset / Trial / NCT01690195

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195

Phase 2 Terminated 343 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

This is a long term extension study to evaluate safety and tolerability of subjects who complete study M11-793 which is evaluating a new treatment for subjects with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.

Timeline

Start
2012-09
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-126 Small molecule 75 mg

Indications